Boston Trust Walden’s LeMaitre Vascular LMAT Stock Holding History

Boston Trust Walden’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$28.5M	Buy	+345,634	New	+$30.6M	0.23%	145

Other funds holding LMAT

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Copeland Capital Management Conshohocken, Pennsylvania $4.34B AUM 17.52% 1-Year Est. Return

Conestoga Capital Advisors Wayne, Pennsylvania $3.31B AUM 6.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return

Boston Trust Walden's LMAT Position: Q3 2026 in Review

Boston Trust Walden opened a new position in LeMaitre Vascular (LMAT) in Q3 2026: 345,634 shares worth $28.5M. The stake represents 0.23% of the portfolio and ranks #145 among its holdings.

96 funds tracked by Wall St. Rank hold LMAT as of Q3 2026.

Boston Trust Walden held 345,634 shares of LeMaitre Vascular worth $28.5M as of Q3 2026.
LeMaitre Vascular was a new Boston Trust Walden position in Q3 2026.
LeMaitre Vascular made up 0.23% of Boston Trust Walden's portfolio in Q3 2026, its #145 holding.
96 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2026.

Based on Boston Trust Walden's 13F filing for Q3 2026, filed 30 Oct 2026.